Navigation Links
Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012

JERUSALEM, November 7, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB: ORMP;, a developer of oral delivery systems, announced today that results of a study performed using its oral insulin formulation, ORMD-0801, have been accepted for presentation at the 12th Annual Diabetes Technology Society Meeting.  The abstract, titled "Concomitant oral and subcutaneous insulin therapy toward stabilization of uncontrolled T1DM," will be presented by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, during the poster session being held from 4pm to 6:30pm (EST), on Thursday, November 8th. The meeting will take place at the Bethesda North Marriott Hotel & Conference Center.

Type 1 Diabetes Mellitus (T1DM), formerly known as juvenile diabetes, affects both young and adult populations. T1DM makes up approximately 5-10% of diabetes cases, and approximately $2 billion of the estimated $15 billion global insulin market. In this form of the disease, an autoimmune reaction destroys the body's insulin-producing cells in the pancreas making its patients completely dependent upon insulin from an external source.

T1DM is occasionally associated with instability and unpredictability of glycemic readings, resulting in poor control of blood sugar.  In severe cases, this condition has a disruptive impact on patient quality of life, due to inadequate clinical solutions. The study to be presented at the Diabetes Technology Society Meeting, and conducted in 2010, evaluated the safety and stabilizing potential of concomitant oral and subcutaneous insulin therapy in volunteers diagnosed with unstable T1DM. Concomitant administration of Oramed's oral insulin formulation, ORMD-0801, and subcutaneous insulin proved safe and well tolerated.  In addition, support with ORMD-0801 led to more frequent blood glucose readings within the healthy range (< 70 mg/dL) and to fewer readings within the high-risk zone (> 200 mg/dL). 

The complete scientific abstract will be available on Oramed's website from the day of the meeting, here.

For additional information on the Diabetes Technology Society Meeting, please visit
their website:, or go directly to the conference agenda.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently approaching FDA-approved Phase 2 clinical trials, and with its GLP-1 analog capsule, currently approaching Phase 1b/2a trials. The company's corporate and R&D headquarters are based in Jerusalem.  

The company's fact sheet can be viewed here.

For more information, the content of which is not part of this press release, please visit

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward looking statements when we discuss the findings of the study to be presented at the Diabetes Technology Society Meeting and say that concomitant administration of oral and subcutaneous insulin proved safe and well tolerated. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Office: +972-2-566-0001       

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
2. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
7. Icahn Issues Statement Regarding Amylin Pharmaceuticals
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
(Date:11/24/2015)... November 24, 2015   ... dietician deliver s advice and insights on ... More than 50% of Dubai ... healthy according to the DHA   femMED launches comprehensive solutions ...    Dubai residents are not consuming enough to ...
(Date:11/24/2015)... Nov. 24, 2015 Abaxis, Inc. (NasdaqGS: ... and consumables for the medical, research, and veterinary markets ... Financial Officer, will present at the 27 th ... 2015 at 11:30 a.m. ET. The conference will be ... New York City . Abaxis, ...
(Date:11/24/2015)... Edelris announce today that they have out-licensed to ... UCBL and ENS-Lyon on a new treatment to cure Hepatitis ... B virus (HBV) infection is a major public health problem ... to 40% of them being at risk of developing chronic ... an effective preventive vaccine, the HBV infection is still rampant ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... , ... Young patients with a wide variety of dental needs can now ... Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment options ... causes minimal discomfort and bleeding to the patient during treatment and the following recovery ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Black Friday sale a week early, offering 40% off select bras and underwear ... apparel industry through both mobile fit technology and the latest fashion, quickly becoming ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced that Dr. Christine Milligan, ... East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... when it comes to several aspects of orthopedic care. They have received recognition ... surgeries and general orthopedic care. , Becker's Hospital Review selected hospitals for ...
(Date:11/24/2015)... , ... November 24, 2015 , ... It takes only ... a business, it is critical that the first impression be positive and reflects business ... not likely to buy anything or want to return. They will also share their ...
Breaking Medicine News(10 mins):